Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab

Nature Reviews Urology volume 8, pages 282–285 (2011)Cite this article

Subjects

Abstract

Background. A 44-year-old patient presented with intermittent macroscopic hematuria on a background of chronic left-sided hydronephrosis and intestinal metaplasia of the bladder. Cystoscopic examination revealed a mass at the dome of the urinary bladder, which was resected. Histopathologic analysis of the specimen confirmed the presence of muscle-invasive adenocarcinoma. Radical cystectomy with curative intent was planned, but review of systems and subsequent CT demonstrated pleural effusion with positive cytology, confirming metastatic disease. Owing to the histologic similarity between this patient's tumor and colorectal cancer, palliative FOLFOX6 (folinic acid, 5-fluorouracil and oxaliplatin) chemotherapy plus bevacizumab was administered. After 3 months of treatment the patient showed a good response, which was sustained for more than 10 months after diagnosis. However, his disease subsequently relapsed, and the patient died shortly thereafter.

Investigation. Physical examination, cystoscopy, transurethral resection of bladder tissue, CT, histopathologic, cytopathologic and immunohistochemical analysis.

Diagnosis. Metastatic adenocarcinoma of the urinary bladder.

Management. 12 cycles of infused and bolus 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX6) plus bevacizumab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Histologic examination of resected tumor tissue.
Figure 2: Immunohistochemical analysis of resected tumor tissue.
Figure 3: CT of the thorax and pelvis at diagnosis and after 3 months of FOLFOX6 treatment.
Figure 4: Pleural fluid cytology.

References

  1. Dahm, P. & Gschwend, J. E. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur. Urol. 44, 672–681 (2003).

    Article  PubMed  Google Scholar 

  2. Lughezzani, G. et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology 75, 376–381 (2010).

    Article  PubMed  Google Scholar 

  3. el-Mekresh, M. M., el-Baz, M. A., Abol-Enein, H. & Ghoneim, M. A. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br. J. Urol. 82, 206–212 (1998).

    Article  CAS  PubMed  Google Scholar 

  4. Siefker-Radtke, A. O. et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J. Urol. 169, 1295–1298 (2003).

    Article  PubMed  Google Scholar 

  5. Corica, F. A. et al. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Urology 50, 427–431 (1997).

    Article  CAS  PubMed  Google Scholar 

  6. Bullock, P. S., Thoni, D. E. & Murphy, W. M. The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer 59, 2086–2090 (1987).

    Article  CAS  PubMed  Google Scholar 

  7. Morton, M. J. et al. Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. Clin. Cancer Res. 13, 6232–6236 (2007).

    Article  CAS  PubMed  Google Scholar 

  8. Smith, A. K., Hansel, D. E. & Jones, J. S. Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma. Urology 71, 915–918 (2008).

    Article  PubMed  Google Scholar 

  9. Ghezala, W. et al. Re: intestinal metaplasia of the bladder. J. Urol. 176, 2309–2310 (2006).

    Article  PubMed  Google Scholar 

  10. Raspollini, M. R., Nesi, G., Baroni, G., Girardi, L. R. & Taddei, G. L. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl. Immunohistochem. Mol. Morphol. 13, 358–362 (2005).

    Article  PubMed  Google Scholar 

  11. Tamboli, P., Mohsin, S. K., Hailemariam, S. & Amin, M. B. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel. Arch. Pathol. Lab. Med. 126, 1057–1063 (2002).

    PubMed  Google Scholar 

  12. Wang, H. L. et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am. J. Surg. Pathol. 25, 1380–1387 (2001).

    Article  CAS  PubMed  Google Scholar 

  13. Nevin, J. E. & Hoffman, A. A. Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. Am. J. Surg. 130, 544–549 (1975).

    Article  CAS  PubMed  Google Scholar 

  14. Logothetis, C. J., Samuels, M. L. & Ogden, S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26, 252–255 (1985).

    Article  CAS  PubMed  Google Scholar 

  15. de Gramont, A. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938–2947 (2000).

    Article  CAS  PubMed  Google Scholar 

  16. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019 (2008).

    Article  CAS  PubMed  Google Scholar 

  17. Hahn, N. M. et al. A multicenter phase II study of cisplatin, gemcitabine, and bevacizumab as first-line chemotherapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU-0475 [abstract 5018]. J. Clin. Oncol. 27 (Suppl.), 15s (2009).

    Google Scholar 

  18. Tran, B. & McKendrick, J. Metastatic urachal cancer responding to FOLFOX chemotherapy. Can. J. Urol. 17, 5120–5123 (2010).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, 24, Dublin, Ireland

    MinYuen Teo & Ray S. McDermott

  2. Department of Histopathology, Adelaide and Meath Hospital incorporating the National Children's Hospital, Tallaght, 24, Dublin, Ireland

    Niall C. Swan

Authors
  1. MinYuen Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niall C. Swan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ray S. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed equally to researching data, discussing content, writing and performing editing/review of the manuscript before submission.

Corresponding author

Correspondence to MinYuen Teo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teo, M., Swan, N. & McDermott, R. Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. Nat Rev Urol 8, 282–285 (2011). https://doi.org/10.1038/nrurol.2011.48

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2011.48

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing